NMD Pharma A/S

CVR 36899069 · Public limited company (A/S) · Active · High risk

NMD Pharma A/S is a Public limited company (A/S), founded on , based in Aarhus N. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 5.9% over the next 12 months, which is 4.2 times the average for Danish companies. 11 annual reports have been published, of which 1 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK 12.4m and a net result of DKK -33.0m. CEO: Thomas Holm Pedersen.

Bankruptcy risk for NMD Pharma A/S

5.9%
probability of bankruptcy within 12 months
High risk

4.2 × the average (1.41%) · higher risk than 93% of active Danish companies

Lowest riskHighest risk

Increases the risk

Return on assets< -20% · bankruptcy rate 16.7%1.9×
Annual reports filed late1 · bankruptcy rate 11.3%1.3×
Loss for the yearYes · bankruptcy rate 10.3%1.2×
Other companies at the same address20–100 · bankruptcy rate 10.2%1.2×

Reduces the risk

Auditor's statementAndet · bankruptcy rate 0.0%0.00×
Equity vs. share capital5+× · bankruptcy rate 2.5%0.28×
Published annual reports10+ · bankruptcy rate 3.0%0.35×
Time since new CEO5+ yrs · bankruptcy rate 3.8%0.43×
Age (years)10–20 yrs · bankruptcy rate 3.9%0.45×
Company typeA/S · bankruptcy rate 4.4%0.50×
Share of late annual reports0.01%–25% · bankruptcy rate 4.5%0.51×
Number of auditors (historical)2 · bankruptcy rate 4.6%0.52×

The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.

Company details

CVR number
36899069
Status
Active
Company type
Public limited company (A/S)
Founded
(11 years)
Address
Palle Juul-Jensens Boulevard 82
8200 Aarhus N
Municipality
Aarhus
Industry
Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Share capital
DKK 5.5m
Employees
18 (2018)
Auditor
EY Godkendt Revisionspartnerselskab
Audit opted out
No

Warning signs

Annual reports filed late1 of 11
Missing annual reportNo
Negative equityNo
Equity ratio53.9%
Current ratio–
Moves (last 2 years)0
CEO changes in total0
CEO's previous bankruptcies0
Other companies at the address20
Going-concern uncertaintyNo

Financials and key figures

Financial year202520242023
Gross profitDKK -26.1mDKK -27.9mDKK -18.8m
Net profitDKK -33.0mDKK -32.3mDKK -22.4m
EquityDKK 12.4mDKK 35.4mDKK 42.7m
Total assetsDKK 23.0mDKK 39.4mDKK 46.4m
CashDKK 21.3mDKK 38.1m–
Short-term debt–DKK 4.0m–
Avg. employees4936–

Latest annual report: Reporting class B · auditor's statement: Independent Auditor’s Report · EY Godkendt Revisionspartnerselskab.

Filed annual reports

Reporting periodPublishedDays after period end
1 Jan 2025 – 31 Dec 2025162
1 Jan 2024 – 31 Dec 2024181
1 Jan 2023 – 31 Dec 2023176
1 Jan 2022 – 31 Dec 2022185 Late
1 Jan 2021 – 31 Dec 2021166
1 Jan 2020 – 31 Dec 2020168
1 Jan 2019 – 31 Dec 2019118
1 Jan 2018 – 31 Dec 2018148
1 Jan 2017 – 31 Dec 2017152
1 Jan 2016 – 31 Dec 2016144
7 May 2015 – 31 Dec 2015146

The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.

Management, owners and auditor

RoleNameFromTo
CEOThomas Holm PedersenCurrent
BoardChristian Ellebæk EllingCurrent
BoardJeremy Paul SpringhornCurrent
BoardMichael Thomas HeffernanCurrent
BoardThomas Holm PedersenCurrent
BoardJoão Carlos Ribas de AlmeidaCurrent
BoardIvan Andreevich BurkovCurrent
BoardAnja Ulrike HarmeierCurrent
BoardMahieddine El Mahdi AïnoucheCurrent
BoardClaus Elsborg Olesen
BoardStephan Christgau
BoardPatrick Volkert Jozef Johannes Vink
BoardMorten Døssing
BoardLucas Antoine de Breed
BoardAnja Ulrike DR Harmeier
BoardPaul Brian Little
BoardFiona MacLaughlin
BoardRoel Bulthuis
BoardMonique Claude Schiersing
BoardSabine Kohar Dandiguian
BoardDavid William Evans
BoardSimone Botti
Owner (15%)LUNDBECKFOND INVEST A/SCurrent
Owner (15%)Novo Holdings A/SCurrent
Owner (10%)Roche Finance Ltd.Current
Owner (33%)Jeito S.L.P.Current
Owner (15%)INKEF Holding Coöperatief U.A.Current
Owner (20%)CLAUS OLESEN HOLDING ApS
Owner (67%)ALSOF Holding ApS
Owner (10%)OBNmotus holding ApS
Owner (5%)CLAUS OLESEN HOLDING ApS
Owner (25%)LUNDBECKFOND INVEST A/S
Owner (25%)Novo Holdings A/S
Owner (5%)Styrelsen for Forskning og Uddannelse
Owner (20%)ALSOF Holding ApS
Owner (5%)ALSOF Holding ApS
Owner (10%)Stichting Depositary Inkef Investment Fund
Owner (10%)Roche Finance Ltd.
Owner (15%)Stichting Depositary Inkef Investment Fund
Owner (15%)Roche Finance Ltd.
Owner (20%)Stichting Depositary Inkef Investment Fund
Owner (20%)Roche Finance Ltd.
Owner (20%)LUNDBECKFOND INVEST A/S
Owner (20%)Novo Holdings A/S
Owner (10%)Jeito S.L.P.
Owner (15%)Stichting Depositary Inkef Investment Fund
Owner (15%)Roche Finance Ltd.
Owner (15%)Jeito S.L.P.
Owner (25%)Jeito S.L.P.
AuditorEY Godkendt RevisionspartnerselskabCurrent
AuditorPRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB
FounderCLAUS OLESEN HOLDING ApSCurrent
FounderALSOF Holding ApSCurrent
FounderOBNmotus holding ApSCurrent

The CEOs' other companies

Thomas Holm Pedersen – 2 other companies

Address history (3 moves)

Palle Juul-Jensens Boulevard 82, 8200 Aarhus N
Palle Juul-Jensens Boulevard 82, 8200 Aarhus N
c/o Capnova A/S, Åbogade 15, 8200 Aarhus N
Sejrs Allé 4A, 8240 Risskov

Former names

NMD Pharma A/S – now
NMD Pharma ApS –

Employees per year

Number of employees at NMD Pharma A/S per year9182016: 720162017: 1520172018: 182018

Other companies at the same address

Similar companies in Aarhus

Questions and answers about NMD Pharma A/S

Has NMD Pharma A/S gone bankrupt?

No, NMD Pharma A/S is not registered as bankrupt in the CVR register. Its status is: active.

What is the bankruptcy risk of NMD Pharma A/S?

Our model estimates a bankruptcy risk of 5.9% over the next 12 months (high risk), which is 4.2 times the average for Danish companies.

Who is the CEO of NMD Pharma A/S?

Thomas Holm Pedersen is the CEO of NMD Pharma A/S.

Who is the auditor of NMD Pharma A/S?

NMD Pharma A/S most recently used EY Godkendt Revisionspartnerselskab.

When was NMD Pharma A/S founded?

NMD Pharma A/S was founded on 7 May 2015.

What is the equity of NMD Pharma A/S?

Equity was DKK 12.4m according to the annual report for the period ending 31 December 2025.

Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.